Immunic is trading 5.2% down at $10.65 after extending a multi-session decline, primarily amid broader biotech weakness.
- No fresh company-specific announcement was identified on September 15, 2026; recent coverage highlights positive analyst views and upcoming Phase 3 multiple-sclerosis results.
- XBI is down 2.11%, alongside higher Treasury yields and cautious risk sentiment.
- Immunic’s September 11 board resignation filing stated there was no operational disagreement.